Capecitabine and 5-FU
Indication: Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
Interactive capecitabine population PK simulator with sequential metabolite modeling from capecitabine to 5'-DFCR, 5'-DFUR, and 5-fluorouracil. Capecitabine is an oral fluoropyrimidine prodrug that is converted to 5-FU, which inhibits thymidylate synthase and disrupts tumor DNA synthesis. Built for colorectal, breast, and gastric cancer PK research and dose exploration.
Drug Overview
Clinical Context
- Molecular Target
- Thymidylate synthase via intracellular conversion to 5-fluorouracil
- Drug Class
- Fluoropyrimidine / Oral Prodrug
- Therapeutic Area
- Oncology
- Indication
- Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
- Route of Administration
- Oral
Model Information
- Model Type
- Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Capecitabine and 5-FU allows you to explore concentration-time profiles under different dosing scenarios. The underlying Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU) model characterizes the pharmacokinetics of this fluoropyrimidine / oral prodrug following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Capecitabine and 5-FU PK simulator?
This is a free, interactive pharmacokinetic simulator for Capecitabine and 5-FU used in Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Capecitabine and 5-FU belong to?
Capecitabine and 5-FU is classified as a Fluoropyrimidine / Oral Prodrug that targets Thymidylate synthase via intracellular conversion to 5-fluorouracil. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Capecitabine and 5-FU. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU) model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
PBPK-PD of ADCs
Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy
Sacituzumab Govitecan (Trodelvy)
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Ready to Simulate?
Launch the Capecitabine and 5-FU simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community